Novo Nordisk A/S- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Novo Nordisk A/S 公司

公司簡介

公司代碼NVO

公司名稱Novo Nordisk A/S

上市日期May 17, 1974

成立日期1931

CEOMr. Lars Fruergaard Joergensen

員工數量76302

證券類型Ordinary Share

年結日May 17

公司地址Novo Alle 1

城市BAGSVAERD

上市交易所The Toronto Stock Exchange

國家Denmark

郵編2880

電話4544448888

網址https://www.novonordisk.com/

公司代碼NVO

上市日期May 17, 1974

成立日期1931

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Ms. Camilla Sylvest

Executive Vice President - Commercial Strategy and Corporate Affairs

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Ms. Tania Sabroe

Executive Vice President - Global People and Organisation

--

Dr. Martin Holst Lange

Executive Vice President - Development

--

Mr. Andreas Fibig

Independent Director

--

Dr. Sylvie L. Gregoire, Pharm.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Ms. Camilla Sylvest

Executive Vice President - Commercial Strategy and Corporate Affairs

--

Mr. Thomas Rantzau

Director, Employee Representative

--

收入明細

單位: USD更新時間: 3月5日週三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Total GLP-1

21.62B

51.35%

Obesity (Saxenda®)

9.44B

22.43%

Long-acting insulin

2.76B

6.57%

Fast-acting insulin

2.68B

6.37%

Rare blood disorders

1.76B

4.17%

Other

3.82B

9.08%

地區USD

名稱

營收

佔比

USA

24.28B

57.64%

EMEA

8.76B

20.79%

Rest of World

4.83B

11.47%

Region China

2.68B

6.37%

Canada

1.56B

3.70%

業務

地區

業務USD

名稱

營收

佔比

Total GLP-1

21.62B

51.35%

Obesity (Saxenda®)

9.44B

22.43%

Long-acting insulin

2.76B

6.57%

Fast-acting insulin

2.68B

6.37%

Rare blood disorders

1.76B

4.17%

Other

3.82B

9.08%

股東統計

更新時間: 2月21日週五

持股股東

股東類型

持股股東

股東統計

佔比

Jennison Associates LLC

0.59%

GQG Partners, LLC

0.38%

Fisher Investments

0.37%

Loomis, Sayles & Company, L.P.

0.34%

Fayez Sarofim & Co.

0.33%

Other

97.96%

持股股東

股東統計

佔比

Jennison Associates LLC

0.59%

GQG Partners, LLC

0.38%

Fisher Investments

0.37%

Loomis, Sayles & Company, L.P.

0.34%

Fayez Sarofim & Co.

0.33%

Other

97.96%

股東類型

股東統計

佔比

Investment Advisor

5.19%

Investment Advisor/Hedge Fund

2.91%

Research Firm

0.78%

Hedge Fund

0.63%

Pension Fund

0.28%

Insurance Company

0.20%

Bank and Trust

0.17%

Holding Company

0.13%

Family Office

0.01%

Other

89.64%

機構持股

更新時間: 2月20日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

2633

348.28M

10.35%

+2.28M

2024Q4

2676

348.53M

10.35%

+330.18K

2024Q3

2529

339.28M

10.15%

-6.04M

2024Q2

2456

341.24M

10.21%

+6.86M

2024Q1

2291

330.24M

9.75%

+10.89M

2023Q4

2037

314.57M

9.30%

+1.47M

2023Q3

1826

307.13M

8.91%

+4.22M

2023Q2

1692

293.83M

8.50%

+768.69K

2023Q1

1603

284.37M

8.30%

-15.91M

2022Q4

1498

293.73M

8.57%

+2.21M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Jennison Associates LLC

19.94M

0.59%

-251.14K

-1.24%

Dec 31, 2024

GQG Partners, LLC

12.99M

0.38%

+5.55M

+74.70%

Dec 31, 2024

Fisher Investments

12.64M

0.37%

-664.98K

-4.99%

Dec 31, 2024

Loomis, Sayles & Company, L.P.

11.57M

0.34%

+2.94M

+34.18%

Dec 31, 2024

Fayez Sarofim & Co.

11.38M

0.33%

-832.63K

-6.81%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.88M

0.29%

-7.78M

-44.05%

Dec 31, 2024

Folketrygdfondet

8.90M

0.26%

+40.31K

+0.45%

Dec 31, 2024

Managed Account Advisors LLC

8.74M

0.25%

+1.20M

+15.97%

Dec 31, 2024

Renaissance Technologies LLC

8.31M

0.24%

+123.68K

+1.51%

Dec 31, 2024

Capital International Investors

6.75M

0.2%

-204.59K

-2.93%

Dec 31, 2024

持股ETF

更新時間: 22 小時前

機構名稱

佔比

Roundhill GLP-1 & Weight Loss ETF

13.7%

Amplify Weight Loss Drug & Treatment ETF

12.09%

VanEck Pharmaceutical ETF

5.89%

iShares Long-Term US Equity Active ETF

4.48%

PGIM Jennison International Opportunities ETF

4.13%

AdvisorShares Gerber Kawasaki ETF

3.74%

TrueShares Technology, AI & Deep Learning ETF

2.72%

PGIM Jennison Better Future ETF

2.43%

North Shore Equity Rotation ETF

2.17%

SP Funds S&P World (ex-US) ETF

1.99%

Roundhill GLP-1 & Weight Loss ETF

佔比13.7%

Amplify Weight Loss Drug & Treatment ETF

佔比12.09%

VanEck Pharmaceutical ETF

佔比5.89%

iShares Long-Term US Equity Active ETF

佔比4.48%

PGIM Jennison International Opportunities ETF

佔比4.13%

AdvisorShares Gerber Kawasaki ETF

佔比3.74%

TrueShares Technology, AI & Deep Learning ETF

佔比2.72%

PGIM Jennison Better Future ETF

佔比2.43%

North Shore Equity Rotation ETF

佔比2.17%

SP Funds S&P World (ex-US) ETF

佔比1.99%

分紅派息

近5年累計派現 21.08B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Aug 06, 2024

NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Aug 26, 2024

Aug 16, 2024

Jan 31, 2024

NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024

Mar 25, 2024

Apr 02, 2024

Mar 22, 2024

Aug 10, 2023

NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023

Aug 21, 2023

Aug 29, 2023

Aug 18, 2023

Feb 02, 2023

NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023

Mar 27, 2023

Apr 04, 2023

Mar 24, 2023

Aug 04, 2022

NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022

Aug 15, 2022

Aug 23, 2022

Aug 12, 2022

Mar 02, 2022

NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022

Mar 28, 2022

Apr 05, 2022

Mar 25, 2022

Aug 05, 2021

NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021

Aug 17, 2021

Aug 25, 2021

Aug 16, 2021

Feb 22, 2021

NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021

Mar 29, 2021

Apr 07, 2021

Mar 26, 2021

Aug 06, 2020

NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020

Aug 17, 2020

Aug 25, 2020

Aug 14, 2020

Feb 06, 2020

NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020

Mar 30, 2020

Apr 07, 2020

Mar 27, 2020

拆合股

公告日期

類型

比率

Aug 14, 2023

Split

1>2

公告日期

類型

比率

Aug 14, 2023

Split

1>2

Novo Nordisk A/S

90.860USD

Novo Nordisk A/S

90.860

概覽

公司